| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 | 10-Q |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Jemperli global net sales of $1.0 billion (£753 million) for the nine months ended September 30, 2026, representing 29% year-over-year growth |
| 02 Oct 2026 |
Form 4: Renton Hollings, Director
Received 5,000 shares by exercise or conversion ($90.2K) · Sold 5,000 shares ($249K) |
| 01 Oct 2026 | 144 |
| 21 Sep 2026 | 10-KT |
| 21 Sep 2026 |
8-K: Financial Statements and Exhibits
Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth |
| 17 Sep 2026 |
Form 4: Orwin John A, Director
Received 1,300 shares by exercise or conversion |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 11 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders
This Amendment No. 1 (this “Amendment”) to the AnaptysBio, Inc. Amended and Restated 2017 Equity Incentive Plan (the “Plan”) was approved and adopted by the Board of Directors (the “Board”) of AnaptysBio, Inc. (the “Company”) on the date... |
| 07 Aug 2026 |
Form 4: Lizzul Paul F., Chief Medical Officer
Granted 16,667 Performance Stock Units |
| 07 Aug 2026 |
Form 4: Faga Daniel, Director
Granted 53,334 Performance Stock Units |
| 30 Jul 2026 |
8-K: Regulation FD Disclosure
As previously disclosed, on November 20, 2025, AnaptysBio, Inc. (the “Company”) filed a Verified Complaint in Delaware Court of Chancery (the “Court”), requesting a court declaration that TESARO, Inc. (“Tesaro”) has materially breached t... |
| 13 Jul 2026 | 144 |
| 30 Jun 2026 | 144 |
| 29 Jun 2026 | 144 |
| 29 Jun 2026 | ARS |
| 29 Jun 2026 | DEFA14A |
| 29 Jun 2026 |
Proxy statement: annual meeting on August 11, 2026
CEO pay $6.1M, down 55% · say-on-pay vote |
| 26 Jun 2026 | 144 |
Loading...